Caris Life Sciences, Inc. (CAI)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Caris Life Sciences CEO Halbert Receives $20.4 Million Compensation
# 🧾 What This Document Is This is a **DEF 14A, or Proxy Statement**, for Caris Life Sciences. You can think of it as a detailed invitation and information packet for the company's upcoming annual shareholder meeting. Its main job is to give shareholders the info they need to vote on important compa
CAI Annual Report Tracks Progress in Building Precision Medicine Platform
# 🧾 What This Document Is This is Caris Life Sciences' **Annual Report to Shareholders (ARS)**. Think of it as the company's comprehensive "year in review" document, sent directly to investors. It combines the formal 10-K financial report with a more visual, strategic overview of the business. You
SEC filings
All filings →Insider trades
All insider trades →Caris Life Sciences, Inc. has no reported insider trades in the last 90 days.